Pavan Vajjah

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Sophie Glatt, Dominique Baeten, Terry Baker et al. · Annals of the Rheumatic Diseases · 2017 · 259 citations · Full text

Medicine, Immunology, Pharmacology +17

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Ralph Adams, Asher Maroof, Terry Baker et al. · Frontiers in Immunology · 2020 · 193 citations · Full text

Life Sciences, Immunology, Pathobiology +17

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

Sophie Glatt, Eric Helmer, Birgit Haier et al. · British Journal of Clinical Pharmacology · 2016 · 144 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942

Gary Burgess, Malcolm Boyce, Margaret M. Jones et al. · EBioMedicine · 2018 · 58 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*

Ruth Oliver, James G. Krueger, Sophie Glatt et al. · British Journal of Dermatology · 2021 · 47 citations · Full text

Medicine, Dermatology, Pharmacology +13